Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed combination verapamil SR/trandolapril

M Dooley1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.

Transplantation proceedings·2017
Same author

Morphological appearance of uterine cavity on ultrasound prior to development of intrauterine adhesions.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Internal medicine journal·2016
Same author

The impact of the introduction of an acute sedation practice guideline.

Acta neuropsychiatrica·2016
Same author

Sport, exercise and the menstrual cycle: where is the research?

British journal of sports medicine·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Verapamil SR/trandolapril effectively manages hypertension without negatively impacting glucose or lipid levels in diabetic patients. This combination therapy demonstrates superior proteinuria reduction and comparable or better antihypertensive efficacy than other treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Essential hypertension is a prevalent cardiovascular condition requiring effective management.
  • Combination therapies are often necessary to achieve blood pressure targets and manage comorbidities.
  • Verapamil sustained-release (SR) and trandolapril are established antihypertensive agents with distinct mechanisms of action.

Purpose of the Study:

  • To evaluate the efficacy and safety of verapamil SR/trandolapril combination therapy.
  • To assess the impact of verapamil SR/trandolapril on metabolic parameters in hypertensive patients with type 2 diabetes.
  • To compare the antihypertensive and cardioprotective effects of verapamil SR/trandolapril with other standard treatments.

Main Methods:

  • Clinical trials involving patients with essential hypertension, including those with type 2 diabetes mellitus.

Related Experiment Videos

  • Assessment of blood pressure reduction, proteinuria levels, and cardiac events.
  • Comparison of verapamil SR/trandolapril with monotherapy and other combination antihypertensive agents.

    • Main Results:

    • Verapamil SR/trandolapril showed no adverse effects on glucose, insulin, or lipid profiles in patients with type 2 diabetes.
    • The combination significantly reduced proteinuria compared to individual components.
    • Antihypertensive efficacy was comparable to atenolol/chlorthalidone and lisinopril/hydrochlorothiazide.
    • Fewer cardiac events were observed in post-myocardial infarction patients with heart failure on verapamil SR/trandolapril compared to trandolapril monotherapy.

    Conclusions:

    • Verapamil SR/trandolapril is a safe and effective treatment for essential hypertension, particularly in patients with type 2 diabetes.
    • The combination offers benefits in proteinuria reduction and cardiovascular event prevention.
    • Adverse event profiles are similar to comparator therapies, supporting its clinical utility.